Laparoscopic myotomy versus pneumatic dilatation for achalasia

ISRCTN ISRCTN05714772
DOI https://doi.org/10.1186/ISRCTN05714772
ClinicalTrials.gov number NCT00188344
Secondary identifying numbers MCT-76449
Submission date
28/07/2005
Registration date
28/07/2005
Last edited
15/02/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Dr David Robert Urbach
Scientific

Toronto General Hospital
200 Elizabeth Street
Eaton Wing 9EN-236A
Toronto, Ontario
M5G 2C4
Canada

Phone +1 416 340 4284
Email david.urbach@uhn.on.ca

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA randomised comparison of laparoscopic myotomy and pneumatic dilatation for achalasia
Study hypothesisIn patients with achalasia, is symptom relief at one year better with laparoscopic Heller myotomy with partial fundoplication, or pneumatic dilatation?
Ethics approval(s)University Health Network Research Ethics Board, approval gained initially on May 19, 2005; renewed and continued approval until May 19, 2007 (reference number: 05-0065-A).
ConditionAchalasia
InterventionIntervention Arm #1 (primary achalasia) will receive pneumatic dilatation
Intervention Arm #2 (primary achalasia) will receive Heller myotomy with partial fundoplication
Intervention Arm #3 (recurrent achalasia) will receive pneumatic dilatation
Intervention Arm #4 (recurrent achalasia) will receive Heller myotomy with partial fundoplication
Intervention typeOther
Primary outcome measureThe achalasia severity questionnaire score at 1 year.
Secondary outcome measures1. Generic health related quality of life (SF-36)
2. Gastrointestinal disease-specific quality of life (GIQLI)
3. Measures of oesophageal physiology (lower oesophageal sphincter pressure, mean amplitude of oesophageal contractions, presence of any contractions after intervention)
4. Gastroesophageal reflux as measured by ambulatory 24-hour oesophageal pH measurement
5. Oesophageal emptying, as quantified by times barium oesophagram
6. Clinical outcomes of care including short term outcomes (i.e. death within 30 days of treatment); major complications (i.e. oesophageal perforation, prolonged hospitalisation, myocardial infarction etc.) and long-term clinical outcomes (i.e. survival after randomisation, incidence of oesophageal cancer, reintervention, clinical gastroesophageal reflux disease, use of antisecretory medications)
Overall study start date01/08/2005
Overall study end date31/08/2012

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants100
Participant inclusion criteria1. Persons of either sex age groups 18 and up
2. Clinical diagnosis of achalasia by a physician
3. Manometric diagnosis of achalasia including both: incomplete relaxation of the lower oesophageal sphincter during swallowing (<80% of elevation over intragastric pressure) and absence of oesophageal peristalsis (peristalsis in <20% of initiated contractions)
4. Facility with English, ability to complete English-language questionnaires
Participant exclusion criteria1. Pseudoachalasia: oesophageal carcinoma; oesophageal stricture; previous oesophageal or gastric surgery; previous instrumentation of the lower oesophageal sphincter i.e. suture, polymer injection, silicone band
2. Previous gastric or oesophageal surgery: fundoplication; Heller myotomy; gastric resection; vagotomy with or without gastric drainage
3. Age 17 years or less
4. Pregnancy
5. Presence of severe comorbid illness: unstable angina; recent myocardial infarction (<6 months), cancer (except integumentary), unless free of disease for more than 5 years; end stage renal disease; previous stroke with cognitive, motor, speech, or swallowing deficit persisting longer than one month; severe respiratory disease; cognitive impairment
Recruitment start date01/08/2005
Recruitment end date31/08/2012

Locations

Countries of recruitment

  • Canada

Study participating centre

Toronto General Hospital
Toronto, Ontario
M5G 2C4
Canada

Sponsor information

University Health Network, Toronto (Canada)
University/education

200 Elizabeth Street
Toronto, Ontario
M5G 2C4
Canada

Phone +1 416 340 4800
Email carolynm@uhnresearch.ca
Website http://www.uhnresearch.ca
ROR logo "ROR" https://ror.org/026pg9j08

Funders

Funder type

Research organisation

Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-76449)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/11/2016 Yes No

Editorial Notes

15/02/2019: Publication reference added.